Oruka Therapeutics, Inc. (ORKA NASDAQ) stock market data APIs
$32.2768
0.5(1.5%)
as of February 13, 2026
Try our APIs with
free plan!
Oruka Therapeutics, Inc. Financial Data Overview
Price chart is built with
Anychart
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
Prev. Close
32.2768
Open
32.7786
High
33.9065
Low
32.2346
52 wk Range
5.49-36.51
Market Cap
1 559 M
Shares Outstanding
48 409 K
EPS
-0.69
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Oruka Therapeutics, Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oruka Therapeutics, Inc. data using free add-ons & libraries
Get Oruka Therapeutics, Inc. Fundamental Data
Oruka Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -125 002 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.7
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oruka Therapeutics, Inc. News
New
Oruka Therapeutics Reports Positive Phase 1 Data For ORKA-002
(RTTNews) - Oruka Therapeutics, Inc. (ORKA) on Monday announced positive interim data from its Phase 1 trial of ORKA-002. The study, conducted in healthy volunteers, evaluated the safety and pharmaco...
Wednesday's ETF Movers: XBI, SLVR
In trading on Wednesday, the SPDR S&P Biotech ETF is outperforming other ETFs, up about 0.7% on the day. Components of that ETF showing particular strength include shares of Oruka Therapeutics, up ab...
Oruka Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
ORKA-001 Phase 1 results presented at EADV show potential for once-per-year dosing, higher efficacy and off-treatment remission Over $500M cash and equivalents provides runway over one year past thre...
Oruka Therapeutics to Present at Multiple November Investor Conferences
MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new ...
Get Oruka Therapeutics, Inc. fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
